Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.16
EXAC's Cash to Debt is ranked lower than
58% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 6.28 vs. EXAC: 0.16 )
EXAC' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 0.16

Equity to Asset 0.74
EXAC's Equity to Asset is ranked higher than
77% of the 358 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. EXAC: 0.74 )
EXAC' s 10-Year Equity to Asset Range
Min: 0.4   Max: 0.88
Current: 0.74

0.4
0.88
Interest Coverage 19.57
EXAC's Interest Coverage is ranked higher than
56% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 205.72 vs. EXAC: 19.57 )
EXAC' s 10-Year Interest Coverage Range
Min: 4.67   Max: 9999.99
Current: 19.57

4.67
9999.99
F-Score: 7
Z-Score: 5.01
M-Score: -2.22
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 10.09
EXAC's Operating margin (%) is ranked higher than
80% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 6.75 vs. EXAC: 10.09 )
EXAC' s 10-Year Operating margin (%) Range
Min: 6.73   Max: 20.53
Current: 10.09

6.73
20.53
Net-margin (%) 6.48
EXAC's Net-margin (%) is ranked higher than
76% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.06 vs. EXAC: 6.48 )
EXAC' s 10-Year Net-margin (%) Range
Min: 4.3   Max: 11.59
Current: 6.48

4.3
11.59
ROE (%) 7.99
EXAC's ROE (%) is ranked higher than
77% of the 363 Companies
in the Global Medical Devices industry.

( Industry Median: 5.79 vs. EXAC: 7.99 )
EXAC' s 10-Year ROE (%) Range
Min: 5.68   Max: 19.05
Current: 7.99

5.68
19.05
ROA (%) 5.87
EXAC's ROA (%) is ranked higher than
79% of the 377 Companies
in the Global Medical Devices industry.

( Industry Median: 3.38 vs. EXAC: 5.87 )
EXAC' s 10-Year ROA (%) Range
Min: 3.79   Max: 9.38
Current: 5.87

3.79
9.38
ROC (Joel Greenblatt) (%) 12.55
EXAC's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 376 Companies
in the Global Medical Devices industry.

( Industry Median: 12.75 vs. EXAC: 12.55 )
EXAC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 8.36   Max: 22.49
Current: 12.55

8.36
22.49
Revenue Growth (%) 6.00
EXAC's Revenue Growth (%) is ranked higher than
74% of the 278 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. EXAC: 6.00 )
EXAC' s 10-Year Revenue Growth (%) Range
Min: 6   Max: 30.5
Current: 6

6
30.5
EBITDA Growth (%) 8.10
EXAC's EBITDA Growth (%) is ranked higher than
82% of the 249 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. EXAC: 8.10 )
EXAC' s 10-Year EBITDA Growth (%) Range
Min: 2.4   Max: 38.1
Current: 8.1

2.4
38.1
EPS Growth (%) 11.90
EXAC's EPS Growth (%) is ranked higher than
83% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: -2.80 vs. EXAC: 11.90 )
EXAC' s 10-Year EPS Growth (%) Range
Min: -8.3   Max: 34.6
Current: 11.9

-8.3
34.6
» EXAC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

EXAC Guru Trades in Q1 2013

Mario Gabelli 642,008 sh (+8.17%)
Jim Simons 17,200 sh (+2.38%)
Chuck Royce 1,017,431 sh (-13.58%)
» More
Q2 2013

EXAC Guru Trades in Q2 2013

Joel Greenblatt 15,150 sh (New)
Mario Gabelli 689,435 sh (+7.39%)
Jim Simons 18,200 sh (+5.81%)
Chuck Royce 1,002,963 sh (-1.42%)
» More
Q3 2013

EXAC Guru Trades in Q3 2013

Jim Simons 24,200 sh (+32.97%)
Chuck Royce 1,007,895 sh (+0.49%)
Joel Greenblatt Sold Out
Mario Gabelli 673,835 sh (-2.26%)
» More
Q4 2013

EXAC Guru Trades in Q4 2013

Mario Gabelli 672,135 sh (-0.25%)
Chuck Royce 987,244 sh (-2.05%)
Jim Simons 23,000 sh (-4.96%)
» More
» Details

Insider Trades

Latest Guru Trades with EXAC

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-09-30 Sold Out 0.01%$18.48 - $21.98 $ 22.4912%0
Joel Greenblatt 2013-06-30 New Buy0.01%$17.9 - $20.76 $ 22.4919%15150
Mario Gabelli 2011-03-31 Reduce -38.57%0.04%$16.25 - $19.17 $ 22.4925%576415
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Exactech, Inc.

Mario Gabelli Ups His Holdings in EXAC, TWIN and LAYN
Mario Gabelli had a busy day on June 26 as he increased his positions in three companies. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.00
EXAC's P/E(ttm) is ranked higher than
81% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 26.70 vs. EXAC: 20.00 )
EXAC' s 10-Year P/E(ttm) Range
Min: 13.61   Max: 38.52
Current: 20

13.61
38.52
P/B 1.58
EXAC's P/B is ranked higher than
83% of the 355 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. EXAC: 1.58 )
EXAC' s 10-Year P/B Range
Min: 1.11   Max: 4.67
Current: 1.58

1.11
4.67
P/S 1.30
EXAC's P/S is ranked higher than
77% of the 378 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. EXAC: 1.30 )
EXAC' s 10-Year P/S Range
Min: 0.85   Max: 3.54
Current: 1.3

0.85
3.54
PFCF 321.29
EXAC's PFCF is ranked lower than
75% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 27.48 vs. EXAC: 321.29 )
EXAC' s 10-Year PFCF Range
Min: 15.45   Max: 353.86
Current: 321.29

15.45
353.86
EV-to-EBIT 14.06
EXAC's EV-to-EBIT is ranked higher than
81% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 20.80 vs. EXAC: 14.06 )
EXAC' s 10-Year EV-to-EBIT Range
Min: 9.1   Max: 25.4
Current: 14.06

9.1
25.4
PEG 1.78
EXAC's PEG is ranked higher than
76% of the 119 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. EXAC: 1.78 )
EXAC' s 10-Year PEG Range
Min: 1.18   Max: 4.5
Current: 1.78

1.18
4.5
Shiller P/E 25.48
EXAC's Shiller P/E is ranked higher than
71% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 26.95 vs. EXAC: 25.48 )
EXAC' s 10-Year Shiller P/E Range
Min: 15.71   Max: 53.41
Current: 25.48

15.71
53.41

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 17.17
EXAC's Price/Net Current Asset Value is ranked lower than
64% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 8.80 vs. EXAC: 17.17 )
EXAC' s 10-Year Price/Net Current Asset Value Range
Min: 4.66   Max: 67.8
Current: 17.17

4.66
67.8
Price/Tangible Book 1.83
EXAC's Price/Tangible Book is ranked higher than
82% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. EXAC: 1.83 )
EXAC' s 10-Year Price/Tangible Book Range
Min: 1.29   Max: 3.73
Current: 1.83

1.29
3.73
Price/DCF (Projected) 2.88
EXAC's Price/DCF (Projected) is ranked lower than
58% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. EXAC: 2.88 )
EXAC' s 10-Year Price/DCF (Projected) Range
Min: 2   Max: 18.69
Current: 2.88

2
18.69
Price/Median PS Value 0.90
EXAC's Price/Median PS Value is ranked higher than
74% of the 334 Companies
in the Global Medical Devices industry.

( Industry Median: 1.10 vs. EXAC: 0.90 )
EXAC' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 1.88
Current: 0.9

0.69
1.88
Price/Peter Lynch Fair Value 2.11
EXAC's Price/Peter Lynch Fair Value is ranked higher than
58% of the 59 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. EXAC: 2.11 )
EXAC' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.99   Max: 4.26
Current: 2.11

0.99
4.26
Price/Graham Number 1.27
EXAC's Price/Graham Number is ranked higher than
82% of the 213 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. EXAC: 1.27 )
EXAC' s 10-Year Price/Graham Number Range
Min: 0.96   Max: 2.15
Current: 1.27

0.96
2.15
Earnings Yield (Greenblatt) 7.10
EXAC's Earnings Yield (Greenblatt) is ranked higher than
83% of the 279 Companies
in the Global Medical Devices industry.

( Industry Median: 4.50 vs. EXAC: 7.10 )
EXAC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.9   Max: 10.9
Current: 7.1

3.9
10.9
Forward Rate of Return (Yacktman) 8.09
EXAC's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 261 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. EXAC: 8.09 )
EXAC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.6   Max: 16.8
Current: 8.09

3.6
16.8

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Exactech, Inc. was incorporated in Florida. The Company develops, manufactures, markets, distributes and sells orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. It manufactures some components of its knee, extremity, and hip joint replacement systems at its facility in Gainesville, Florida, utilizing modern, highly automated computer aided manufacturing equipment. The company's cellular based manufacturing processes, which are organized in groups, or cells, are dedicated to specific product lines to minimize change-over and increase efficiency, and are designed to help it reduce the company's production cycle times while permitting flexibility to adjust quickly to changes in demand. To supplement its manufacturing of components, the company has formed strategic alliances with suppliers and business partners to externally manufacture some components. Additionally, it acquires and distributes other products and services through exclusive agreements, such as its agreement with Tecres (r) S.p.A, and non-exclusive agreements, such as with RTI Biologics, Inc. or RTI and Biomatlante SARL. In marketing its products, the company uses a combination of traditional targeted media marketing together with its main marketing focus, direct customer contact and service to orthopaedic surgeons. Products include: Knee Implants, Hip Implants, Biologics and Spine, Extremities.The Company markets its orthopaedic implant products in the United States through a network of independent sales agencies and direct sales representatives. Its competitors in the orthopaedic device market are DePuy, Inc., a division of Johnson and Johnson, Zimmer, Inc., a subsidiary of Zimmer Holdings, Inc., Stryker Howmedica Osteonics, a subsidiary of Stryker Corp., Smith and Nephew plc, and Biomet Orthopaedics, a subsidiary of Biomet, Inc. Healthcare is heavily regulated by the federal government and by state and local governments.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide